This study aimed to evaluate the initial experience using EUS-FNA in a newly establish tertiary hospital based program. Methods: A consecutive series of 501 EUS examinations performed over a 34-month period was reviewed retrospectively. All procedures were performed by a single operator. In 104 cases, EUS-FNA was undertaken for evaluation of solid pancreatic lesions or mediastinal

adenopathy. The final diagnosis of pancreatic solid lesions was determined by surgical histology or extended clinical MS-275 manufacturer follow-up. Results: EUS-FNA was performed in 104 patient and involved sampling of 61 solid pancreatic lesions and 43 mediastinal lymph nodes. In regards to pancreatic

lesions; mean patient age was 67 years ± 12 Selleckchem Inhibitor Library years and 64% were in males. Mean number of passes made was 4. FNA diagnoses were: 35 malignant (57%), 6 suspicious (10%), 4 atypical (7%), 10 inadequate (16%) and 6 benign (10%). Positive cytology revealed: adenocarcinoma (29), non-small cell carcinoma (2), lymphoma (1), neuroendocrine (1), adenosquamous (1) and poorly differentiated carcinoma (1). The overall diagnostic utility of EUS-FNA for solid pancreatic lesions (including cases of inadequate cellularity and non-diagnostic cases) showed a sensitivity of 84%, specificity 94%, positive predictive value 97%, negative predictive value 68% and accuracy 87%. Regarding mediastinal adenopathy; mean age was 61 years ± 14 years and 58% were male. Mean number of passes made was 4. FNA Diagnoses were: 16

malignant (37%), 1 atypical (2%), 6 sarcoidosis (14%), 6 non-diagnostic (14%), and 14 benign (33%). Positive cytology revealed: sarcoidosis Celecoxib (7), adenocarcinoma (5), non-small cell carcinoma (5), lymphoma (3), neuroendocrine tumor (1) and poorly differentiated tumor (1). Complications were observed in 2 of 104 (1.9%) cases within 24 hours following FNA. There was a single case of mild pancreatitis and a single case of oesophageal perforation. Both cases were admitted and made full recovery with conservative management. Conclusion: EUS-FNA is a safe, minimally invasive and effective means of initial histological assessment of mediastinal adenopathy and solid lesions of the pancreas. S CHANDRAN,1 M EFTHYMIOU1, A KAFFES,2 V KWAN,3 JW CHEN,4 M MURRAY,5 D WILLIAMS,6 C WELCH,7 A CHONG,8 S GUPTA,9 W TAM,10 B DEVEREAUX,11 N NGUYEN,12 R VAUGHAN1 1Department of Gastroenterology Austin Health, 2RPA (NSW), 3Westmead (NSW), 4Flinders Medical Centre (SA), 5Pindara Private Hospital (QLD), 6St. Vincent’s Hopital (NSW), 7Townsville Hospital (QLD), 8Fremantle Hospital (WA), 9Princess Alexandra (QLD), 10Lyel McEwin (SA), 11RBH(QLD), 12North Eastern Community Hospital.